Literature DB >> 18661545

Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB.

Isabelle Boileau1, Jerry J Warsh, Mark Guttman, Jean A Saint-Cyr, Tina McCluskey, Pablo Rusjan, Sylvain Houle, Alan A Wilson, Jeffrey H Meyer, Stephen J Kish.   

Abstract

This study investigated whether abnormalities in serotonin transporter binding occur in Parkinson's disease (PD) patients with concurrent depression. We estimated serotonin transporter levels in seven clinically depressed early-stage PD patients and in seven healthy matched-control subjects during a single positron emission tomography (PET) scan with the serotonin transporter radioligand, [(11)C]DASB. Depressed PD patients displayed a wide-spread increase (8-68%) in [(11)C]DASB specific binding outside of the striatum, which was significant in dorsolateral (37%) and prefrontal (68%) cortices. Elevated [(11)C]DASB binding was positively correlated with depressive symptoms but not with disease severity or duration. Compatible with recent PET/[(11)C]DASB findings in major depression, the present preliminary data suggest that increased [(11)C]DASB binding, possibly reflecting greater serotonin transporter density (up-regulation), might be a pathological feature of depression in Parkinson's disease-and possibly a characteristic of depressive illness in general. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18661545     DOI: 10.1002/mds.22212

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  41 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.

Authors:  Karl Strecker; Florian Wegner; Swen Hesse; Georg-Alexander Becker; Marianne Patt; Philipp M Meyer; Donald Lobsien; Johannes Schwarz; Osama Sabri
Journal:  J Neurol       Date:  2010-07-21       Impact factor: 4.849

Review 3.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

4.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

5.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

Review 6.  Imaging insights into basal ganglia function, Parkinson's disease, and dystonia.

Authors:  A Jon Stoessl; Stephane Lehericy; Antonio P Strafella
Journal:  Lancet       Date:  2014-06-18       Impact factor: 79.321

7.  In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.

Authors:  Andre C Felicio; Katherine Dinelle; Pankaj A Agarwal; Jessamyn McKenzie; Nicole Heffernan; Jeremy D Road; Silke Appel-Cresswell; Zbigniew K Wszolek; Matthew J Farrer; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Mov Disord       Date:  2014-05-05       Impact factor: 10.338

Review 8.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 9.  Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Authors:  Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2017-07-12       Impact factor: 3.575

Review 10.  Imaging phenotypes of major depressive disorder: genetic correlates.

Authors:  J B Savitz; W C Drevets
Journal:  Neuroscience       Date:  2009-04-07       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.